| Title |
Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
|
|---|---|
| Published in |
Journal of Endocrinological Investigation, August 2014
|
| DOI | 10.1007/s40618-014-0163-9 |
| Pubmed ID | |
| Authors |
G. T. Russo, A. M. Labate, A. Giandalia, E. L. Romeo, P. Villari, A. Alibrandi, G. Perdichizzi, D. Cucinotta |
| Abstract |
In addition to the effects on glycemic control and body weight, GLP-1 receptor agonists may favorably affect other major cardiovascular disease (CVD) risk factors, although currently available data are still sparse. In this retrospective study, we evaluated the effects of 12-month treatment with liraglutide on major CVD risk factors in 115 type 2 diabetes outpatients (60 men and 55 women), on stable hypoglycemic, anti-hypertensive and/or lipid-lowering therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 23% |
| Student > Master | 10 | 18% |
| Researcher | 6 | 11% |
| Student > Postgraduate | 4 | 7% |
| Student > Bachelor | 3 | 5% |
| Other | 7 | 12% |
| Unknown | 14 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 47% |
| Agricultural and Biological Sciences | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Environmental Science | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 15 | 26% |